News & Views: 4/12 - 4/18

April 19, 2022

The Senate and House Diabetes Caucuses released their bicameral, bipartisan insulin pricing priorities.

The priorities build on Sens. Shaheen and Collins previous work by encouraging manufacturers to reduce list prices while extending patient protections. The new priorities aim to increase competition and access to insulin products. The proposal specifically bans rebates on insulin products that are priced at 2006 levels, limits coinsurance to $35 for insured patients, and prohibits insurers from denying coverage of insulin. Sens. Shaheen and Collins have requested input from their colleagues and all stakeholders on their proposal before they introduce the final legislation. To read the full press release, click here.  

CIDSA Experts in the News

Ameet Sarpatwari and colleagues from Harvard Medical School opined on the manufacturer restrictions of the 340B program in a JAMA Viewpoint article. The researchers outline the program’s history and past changes that have made the program into what it is today before discussing the possible implications of the manufacturers’ restrictions. They conclude by recommending Congress (1) allow contract pharmacies to participate in 340B and (2) empower HRSA with rulemaking abilities to prevent drug diversion and duplicate discounts. To read the full article, click here.

View Full Article
Want to submit an Insight to be featured by CIDSA?
If you have performed research or written opinion pieces we want to see them. Please use the link below to submit your work.
Back to all Insights >